Status:
NOT_YET_RECRUITING
Efficacy of Subcutaneous Infliximab in Acute Severe Ulcerative Colitis: a Multicenter Retrospective Study
Lead Sponsor:
Central Hospital, Nancy, France
Conditions:
Ulcerative Colitis
Eligibility:
All Genders
18+ years
Brief Summary
Around 25% of patients with ulcerative colitis will develop acute severe colitis during the course of their disease. The first-line treatment for acute severe colitis is intravenous corticosteroid the...
Eligibility Criteria
Inclusion
- Patient ≥ 18 years old
- Diagnosis of acute severe ulcerative colitis according to Truelove Witts criteria
- Patients treated with at least one injection of subcutaneous Infliximab after induction with two or three intravenous perfusions of Infliximab
- Patients with a follow-up of at least 12 months after the first subcutaneous injection
- 12-month data available in medical records
- Patient who has received full information about the organization of the research and who has not objected to his or her participation and to the use of his or her data.
Exclusion
- Patients with intravenous Infliximab as a maintenance treatment
- Patients switched from intravenous to subcutaneous form during follow-up, and who received more than three intravenous perfusions
- Protected persons.
Key Trial Info
Start Date :
June 1 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2025
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT06998797
Start Date
June 1 2025
End Date
October 1 2025
Last Update
May 31 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.